- Coleman, Paul;
- de Lecea, Luis;
- Gotter, Anthony;
- Hagan, Jim;
- Hoyer, Daniel;
- Kilduff, Thomas;
- Kukkonen, Jyrki P;
- Porter, Rod;
- Renger, John;
- Siegel, Jerome M;
- Sutcliffe, Gregor;
- Upton, Neil;
- Winrow, Christopher J
Orexin receptors (nomenclature as agreed by theNC-IUPHARSubcommittee on Orexin receptors [42]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [109]. Currently the only orexin receptor ligands in clinical use are suvorexant and lemborexant, which are used as hypnotics. Orexin receptor crystal structures have been solved [134, 133, 54, 117, 46].